CO5261628A1 - COMPOUNDS - Google Patents

COMPOUNDS

Info

Publication number
CO5261628A1
CO5261628A1 CO00084360A CO00084360A CO5261628A1 CO 5261628 A1 CO5261628 A1 CO 5261628A1 CO 00084360 A CO00084360 A CO 00084360A CO 00084360 A CO00084360 A CO 00084360A CO 5261628 A1 CO5261628 A1 CO 5261628A1
Authority
CO
Colombia
Prior art keywords
optionally substituted
independently selected
alkyl
heteroatoms independently
integer
Prior art date
Application number
CO00084360A
Other languages
Spanish (es)
Inventor
Joseph Abedi
Daniel Carcanague
Thomas Kuhler
Shue Youe-Kong
Mark Wuonola
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO5261628A1 publication Critical patent/CO5261628A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un compuesto de la fórmula I o una sal o solvato farmacéuticamente aceptable del mismo<EMI FILE="00084360_1" ID="1" IMF=JPEG >en donde:X es S; SO2; NH; N(alquil C1-6); O o CH2;Y es alquil C1-6; O(cicloalquil C3-8); O(alquil C1-6); Hal; CHal3, CHHal2, CH2Hal, OCHal3, OCHHal2 o OCH2Hal, donde Hal representa halógeno; NRR´, donde R y R´ independientemente representan H o alquil C1-8, o NRR´ representa un anillo heterocíclico C3-8 opcionalmente substituido que contiene opcionalmente 1, 2 o 3 heteroátomos adicionales independientemente seleccionados entre O, N y S; H; COOR´´ o COR´´, R´´ que representa H o alquil C1-6; o CH2OH; R1 es (CH2)a-R3; -((CH2)bO)c-R3; -(CH2)d-R3,; -(CH2)aC(=O)R3; -(CH2)dC(=O)R3,; -((CH2)e-O)cAND#39-(CH2)f-R3,;.R3 o R3,; R2 es un heterociclo mono- o bi-cíclico de 5-, 6-, 7-, 8-, 9- o 10-miembros opcionalmente substituido que contiene 1, 2, 3, 4, 5 o 6 heteroátomos independientemente seleccionados entre O, N y S; R3 es H; alquil C1-6; cicloalquil C3-8 opcionalmente substituido que contiene opcionalmente 1, 2 o 3 heteroátomos independientemente seleccionados entre O, N y S; o una estructura de anillos aromáticos C5-10 opcionalmente substituida, que contiene opcionalmente 1, 2 o 3 heteroátomos independientemente seleccionados entre O, N y S; o una estructura de anillos heterocíclicos mono- o bi-cíclicos de 5- a 10-miembros opcionalmente substituidos que contienen 1, 2, 3, 4 o 5 heteroátomos independientemente seleccionados entre O, N y S; R3´ es -Z-M donde Z representa O, S o NH y M representa H, una estructura de anillos heterocíclicos mono- o bi- cíclicos de 5-, 6-, 7-, 8-, 9- o 10-miembros - 2 -opcionalmente substituida que contienen 1, 2, 3, 4, 5 o 6 heteroátomos independientemente seleccionados entre O, N y S, o una estructura de anillos aromáticos C5-10 opcionalmente substituida que contiene opcionalmente 1, 2 o 3 heteroátomos independientemente seleccionados entre O, N y S; o -Z-M representa -C(=O)NR6R7, -NR7R, -OC(=O)NR8R9, -NC(=O)NR8R9 o -NC(=O)R8; Para R6 y R7, o bien: R6 es H; alquil C1-12; cicloalquil C3-8 opcionalmente substituido y opcionalmente fusionado a un anillo benzo; (alquil C1-8)aril opcionalmente substituido donde el aril es C6-10; (alquil C1-8)R opcionalmente substituido, donde R representa un heterociclo mono- o bi-cíclico de 5-, 6-, 7-, 8-, 9- o 10-miembros que contiene 1, 2, 3, 4, 5 o 6 heteroátomos independientemente seleccionados entre O, N y S o R representa un cicloalquil C3-13 mono-, bi- o tri-cíclico; aril C6-10 opcionalmente substituido; un heterociclo mono- o bi-cíclico de 5-, 6-, 7-, 8-, 9- o 10-miembros opcionalmente substituido que contiene 1, 2, 3, 4, 5 o 6 heteroátomos independientemente seleccionados entre O, N y S; o -C(=O)O-Ar, donde Ar representa aril C6-10 opcionalmente substituido; y R7 es H; ola estructura -NR6R7 representa un anillo heterocíclico C3-8 que contiene opcionalmente 1, 2 o 3 heteroátomos adicionales independientemente seleccionados entre O, N y S, -NR6R7 que es opcionalmente substituido; a representa un entero 1, 2, 3, 4 o 5; cada b independientemente representa un entero 1, 2, 3, 4 o 5;c representa un entero 1, 2, 3, 4 o 5; cAND#39 representa un entero 1, 2, 3, 4 o 5; d representa un entero 1, 2, 3, 4 o 5; cada e independientemente representa un entero 1, 2, 3, 4 o 5;f representa un entero 1, 2, 3, 4 o 5; y g representa cero o un entero 1, 2, 3, 4 o 5. o una sal o solvato farmacéuticalmente aceptable del mismo.A compound of the formula I or a pharmaceutically acceptable salt or solvate thereof <EMI FILE = "00084360_1" ID = "1" MFI = JPEG> wherein: X is S; SO2; NH; N (C1-6 alkyl); O or CH2; Y is C1-6 alkyl; O (C3-8 cycloalkyl); O (C1-6 alkyl); Hal; CHal3, CHHal2, CH2Hal, OCHal3, OCHHal2 or OCH2Hal, where Hal represents halogen; NRR ', where R and R' independently represent H or C1-8 alkyl, or NRR 'represents an optionally substituted C3-8 heterocyclic ring optionally containing 1, 2 or 3 additional heteroatoms independently selected from O, N and S; H; COOR´´ or COR´´, R´´ which represents H or C1-6 alkyl; or CH2OH; R1 is (CH2) a-R3; - ((CH2) bO) c-R3; - (CH2) d-R3 ;; - (CH2) aC (= O) R3; - (CH2) dC (= O) R3 ,; - ((CH2) e-O) cAND # 39- (CH2) f-R3,;. R3 or R3 ,; R2 is an optionally substituted mono- or bi-cyclic 5-, 6-, 7-, 8-, 9- or 10-membered heterocycle containing 1, 2, 3, 4, 5 or 6 heteroatoms independently selected from O, N and S; R3 is H; C1-6 alkyl; optionally substituted C3-8 cycloalkyl optionally containing 1, 2 or 3 heteroatoms independently selected from O, N and S; or an optionally substituted C5-10 aromatic ring structure, optionally containing 1, 2 or 3 heteroatoms independently selected from O, N and S; or an optionally substituted 5- or 10-membered 5- or 10-membered heterocyclic ring structure containing 1, 2, 3, 4 or 5 heteroatoms independently selected from O, N and S; R3 'is -ZM where Z represents O, S or NH and M represents H, a 5-, 6-, 7-, 8-, 9- or 10-membered heterocyclic ring structure. optionally substituted containing 1, 2, 3, 4, 5 or 6 heteroatoms independently selected from O, N and S, or an optionally substituted C5-10 aromatic ring structure that optionally contains 1, 2 or 3 heteroatoms independently selected from O , N and S; or -Z-M represents -C (= O) NR6R7, -NR7R, -OC (= O) NR8R9, -NC (= O) NR8R9 or -NC (= O) R8; For R6 and R7, or: R6 is H; C1-12 alkyl; C3-8 cycloalkyl optionally substituted and optionally fused to a benzo ring; (C1-8 alkyl) optionally substituted aryl where the aryl is C6-10; (optionally substituted C1-8 alkyl) R, where R represents a 5-, 6-, 7-, 8-, 9- or 10-membered mono- or bi-cyclic heterocycle containing 1, 2, 3, 4, 5 or 6 heteroatoms independently selected from O, N and S or R represents a mono-, bi- or tri-cyclic C3-13 cycloalkyl; C6-10 aryl optionally substituted; an optionally substituted mono- or bi-cyclic 5-, 6-, 7-, 8-, 9- or 10-membered heterocycle containing 1, 2, 3, 4, 5 or 6 heteroatoms independently selected from O, N and S; or -C (= O) O-Ar, where Ar represents optionally substituted C6-10 aryl; and R7 is H; The structure -NR6R7 represents a C3-8 heterocyclic ring optionally containing 1, 2 or 3 additional heteroatoms independently selected from O, N and S, -NR6R7 which is optionally substituted; a represents an integer 1, 2, 3, 4 or 5; each b independently represents an integer 1, 2, 3, 4 or 5; c represents an integer 1, 2, 3, 4 or 5; cAND # 39 represents an integer 1, 2, 3, 4 or 5; d represents an integer 1, 2, 3, 4 or 5; each and independently represents an integer 1, 2, 3, 4 or 5, f represents an integer 1, 2, 3, 4 or 5; and g represents zero or an integer 1, 2, 3, 4 or 5. or a pharmaceutically acceptable salt or solvate thereof.

CO00084360A 1999-11-09 2000-11-07 COMPOUNDS CO5261628A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9904044A SE9904044D0 (en) 1999-11-09 1999-11-09 Compounds

Publications (1)

Publication Number Publication Date
CO5261628A1 true CO5261628A1 (en) 2003-03-31

Family

ID=20417650

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00084360A CO5261628A1 (en) 1999-11-09 2000-11-07 COMPOUNDS

Country Status (4)

Country Link
AU (1) AU1746401A (en)
CO (1) CO5261628A1 (en)
SE (1) SE9904044D0 (en)
WO (1) WO2001034573A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
WO2001060819A1 (en) * 2000-02-18 2001-08-23 Kirin Beer Kabushiki Kaisha Novel isoxazole and thiazole compounds and use thereof as drugs
SE0100902D0 (en) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
AR035966A1 (en) 2001-05-18 2004-07-28 Altana Pharma Ag A BENCILAMINOPIRIMIDINE COMPOUND, A MEDICINAL PRODUCT THAT INCLUDES IT AND THE USE OF IT
SE0103710D0 (en) 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
SE0202539D0 (en) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0403085D0 (en) 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
SE0403086D0 (en) 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
JP5592265B2 (en) 2007-11-01 2014-09-17 アキュセラ インコーポレイテッド Amine derivative compounds for the treatment of eye diseases and disorders
CN110156752B (en) * 2019-05-28 2021-03-19 沈阳药科大学 2- [ (pyridine-2-ylmethyl) sulfenyl ] -1H-benzimidazole compound and application thereof
US11970489B1 (en) 2023-10-23 2024-04-30 King Faisal University 4-[(substituted 1H-benzimidazol-2-ylsulfanyl)methyl]-6-substituted-2H-chromen-2-ones as larvicidal agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5768886A (en) * 1985-05-24 1986-11-27 G.D. Searle & Co. 2-((1-h-benzimidazol-2-ylsulfinyl)methyl)benzenamines
EP0251536A1 (en) * 1986-06-24 1988-01-07 FISONS plc Benzimidazoles, their production, formulation and use as gastric acid secretion inhibitors
JPH06298611A (en) * 1993-04-16 1994-10-25 Nippon Chemiphar Co Ltd Antibacterial agent

Also Published As

Publication number Publication date
WO2001034573A1 (en) 2001-05-17
AU1746401A (en) 2001-06-06
SE9904044D0 (en) 1999-11-09

Similar Documents

Publication Publication Date Title
CO5261628A1 (en) COMPOUNDS
AR046193A2 (en) DERIVATIVES OF PIPERIDIL OR PIPERAZINIL 1,2,3,4-TETRAHIDRONAFTALENO REPLACED, PHARMACEUTICAL FORMULATION, USES IN THE MANUFACTURE OF MEDICINES, AND PROCESS FOR PREPARATION
NO20015447D0 (en) Quinoline derivatives as inhibitors of MEK enzymes
RU95108329A (en) Thiazolidine dione, process for preparation thereof, and pharmcomposition
AR029216A1 (en) NON-PEPTIDIC INHIBITING COMPOUNDS OF THE VLA-4 DEPENDENT CELL UNION IN THE TREATMENT OF INFLAMMATORY, AUTOIMMUNE AND RESPIRATORY DISEASES; PHARMACEUTICAL COMPOSITION AND TREATMENT PROCEDURE
DK1546134T3 (en) Piperazine-substituted arylbenzodiazepines
CO5170521A1 (en) PIRIMIDINONE PHARMACEUTICAL COMPOUNDS
NO904377L (en) TRICYCLIC CARBAPNAM COMPOUNDS.
NO930891L (en) NEW DIARYL SULPHONAMIDES
AR006360A1 (en) DERIVATIVES OF 1,2,3,4-TETRAHIDRONAFTALENO SUBSTITUTED, USE OF THE SAME FOR THE PREPARATION OF MEDICINES AND PROCEDURE FOR THE PREPARATION.
NO20015446L (en) Quinoline derivatives as inhibitors of MEK enzymes
DE3777852D1 (en) DEKAHYDROCHINOLIN DERIVATIVES, METHOD FOR THEIR PRODUCTION, INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION, THEIR USE AS MEDICINAL PRODUCTS AND PREPARATIONS THEREOF.
BR1100983A (en) New compounds derived from bezimidazole, process for preparing compounds, pharmaceutical compositions, and use of derivatives
ATE154021T1 (en) N-CYCLOHEXYL BENZAMIDE DERIVATIVES, THEIR PREPARATIONS AND THERAPEUTIC USES
BR9812239A (en) Compound, pharmaceutical formulation, use of the compound, processes for the treatment of disorders, for the treatment of disorders mediated by 5-hydroxytryptamine, and for the preparation of the compound
FI905855A0 (en) Process for Preparation of Therapeutically Useful / (3aS-cis) -1,2,3,3a, 8,8a-Hexahydropyrrolo / 2,3-b / indol-5-yl / aminocarbonyl / carbamate derivative
CO5280081A1 (en) ANTIBACTERIALS OF PIPERIDINYLOXY OXAZOLIDINONE, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND PROCESS FOR PREPARATION
CO5180647A1 (en) DERIVATIVES OF OCTAHIDRO-1H-PIRIDO [1,2-A] PIRAZINA 2,7- REPLACED AS LIGANDOS FOR SEROTONINE RECEPTORS
KR950704309A (en) SULFONAMIDE DERIVATIVES OF BENZENEFUSED HYDROXY SUBSTITUTED CYCLOALKYL AND HETEROCYCLIC RING COMPOUNDS
CO5261610A1 (en) COMPOUNDS
ES2054502T3 (en) ESTERS OF ACID 10- (1-HYDROXYETHYL) -11-OXO-1-AZATRICICLO (7.2.0.0 (3.8)) - UNDEC-2-EN-2-CARBOXILICO AND A PROCEDURE FOR ITS PREPARATION.
SE8207092L (en) PROCEDURE FOR MANUFACTURING OPTICALLY ACTIVE PENEMS
ATE204278T1 (en) SEROTONINERGIC ERGOLINE DERIVATIVES
NO840131L (en) PROCEDURE FOR THE PREPARATION OF NEW BICYCLO (4.2.0) 1,3,5-OCTARIAN DERIVATIVES
DE3667789D1 (en) PIPERAZINE-1-YL ERGOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.

Legal Events

Date Code Title Description
FA Application withdrawn